PE-22-28 — Vendor Pricing & Purity Guide
Research Overview
PE-22-28 is a synthetic heptapeptide derived from the neuroprotective protein Spadin. It acts as an antagonist of TREK-1, a two-pore potassium channel involved in neuronal excitability and mood regulation. TREK-1 blockade has antidepressant-like effects similar to SSRIs but with a faster onset of action in preclinical models.
PE-22-28 represents a novel mechanism for mood regulation — targeting ion channels rather than monoamine neurotransmitter systems. In rodent studies, it produced antidepressant and neurogenic effects within days rather than weeks.
Key Research Findings
- •Antidepressant effects via TREK-1 channel antagonism — a novel non-monoamine mechanism
- •Faster onset than SSRIs in rodent depression models
- •Promoted hippocampal neurogenesis, suggesting neuroplasticity-enhancing effects
- •Improved spatial memory in addition to antidepressant activity
- •Derived from Spadin, a naturally occurring neuroprotective peptide
Research Dosage Protocols
PE-22-28 is supplied as lyophilized powder. Research doses in rodent models range from 100-500 mcg/kg via intraperitoneal injection. No human studies have been conducted.
For research reference only. Not medical advice. Not for human consumption.
Price Comparison (5 products from 5 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Pure Rawz | $65.02 $6.50/mg 10mg vial | In Stock |
| Core Peptides | $54.00 $6.75/mg 8mg vial | In Stock |
| Biotech Peptides | $55.00 $6.88/mg 8mg vial | In Stock |
| Soma Chems | $74.99 $7.50/mg 10mg vial | In Stock |
| Peptide Sciences | $60.00 $7.50/mg 8mg lyophilized | In Stock |
Frequently Asked Questions
What is PE-22-28?
PE-22-28 is a heptapeptide TREK-1 antagonist with antidepressant and neurogenic effects. It works through ion channel modulation rather than serotonin/monoamine pathways, with faster onset than SSRIs in animal models.